CARMEL, Ind., Oct. 22, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, announced today that it will report financial results for the three months ended September 30, 2024, on Tuesday, October 29, 2024, before the market opens. The Company has scheduled a conference call that same day, October 29, at 9:00 a.m. ET, to review the results.
Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://dev.syrahealth.com/ir/presentations/q3-2024-earnings-call.
Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast replay will be available in the Investors section of the Company's website at https://dev.syrahealth.com/ir/presentations/q3-2024-earnings-call.
ABOUT SYRA HEALTH CORP.
Syra Health leads the charge in addressing the toughest challenges in healthcare, from behavioral and mental health to population health, digital transformation, health education, and workforce development. Our technology-driven solutions focus on prevention, accessibility, and affordability, ensuring that every patient and provider gets the support they need. We proudly partner with payers, providers, life sciences organizations, academic institutions, and government entities to advance healthcare and improve outcomes. Learn more about our mission and services at www.syrahealth.com.
Contact
For Media or Investor Inquiries:
Christine Drury
Syra Health
IR/PR Director
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.06 |
| Daily Change: | -0.006 -8.96 |
| Daily Volume: | 97,123 |
| Market Cap: | US$692K |
February 18, 2025 December 02, 2024 November 26, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
